Epsilogen Ltd
Other research and experimental development on natural sciences and engineering · London
ActiveUnited KingdomIncorporated 2016Private Limited Company
Documents & history
Available account evidence and business events. This is not a complete filing history or document library.
Accounts to 2025-12-31
IXBRL · 361 source facts · 13 selected values
Validation findingsXBRL valid
Accounts to 2025-12-31
IXBRL · 361 source facts · 13 selected values
Validation findings
XBRL valid
- Reporting period
- 2025-01-01 to 2025-12-31
- Extraction status
- complete
- Numeric facts
- 233
- Documents processed
- 1
- XBRL standards validation
- valid
- Filing-profile validation
- invalid
- Parser
- arelle 2.44.4
- Taxonomy
- IFRS-2026-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod223_4319_10295520_20251231
- Source archive
- Accounts_Bulk_Data-2026-10-01.zip
Extraction findings: filing rules invalid. These describe source processing, not an audit opinion on the company.
Registered details
10295520- Status
- Active
- Type
- Private Limited Company
- Incorporated
- 2016-07-26
- Jurisdiction
- —
- Registered office
- WATERFRONT, ARC WEST LONDON, MANBRE ROAD, LONDON, W6 9RH, UNITED KINGDOM
Classification
1 SIC codes72190
Capital & company events
Reconstructed equity rounds and matched research funding.
Equity fundraising
4 SH01-derived rounds2025-08-11
£10,750,000 raised
£103,244,070 estimated post-money
2024-08-29
£12,487,934 raised
£32,014,298 estimated post-money
2023-12-15
£5,005,428 raised
£39,090,405 estimated post-money
2022-02-24
£17,037,242 raised
£33,037,518 estimated post-money
Research and innovation
4 matched grantsPreclinical validation of a novel cancer immunotherapeuticLeadInnovate UK · Study · 2020-10-01 – 2022-12-31 · with 1 other participant£492,545awarded
Preclinical validation of a novel cancer immunotherapeuticLead
Innovate UK · Study · 2020-10-01 – 2022-12-31 · with 1 other participant
£492,545
awarded
Epsilogen Ltdlead£492,545
Next generation antibody treatments for ovarian cancerLead
Innovate UK · Study · 2020-05-01 – 2021-10-31
£348,520
awarded
Discovery of next generation HER2 antibodies for the treatment of cancerLead
Innovate UK · Feasibility Studies · 2019-01-01 – 2020-11-30
£523,217
awarded
Development of a novel immuno-oncology drug targeting solid tumoursLead
Innovate UK · Collaborative R&D · 2018-04-01 – 2020-06-30
£1,018,198
awarded